Benitec Biopharma(BNTC)

Focus: Benitec Biopharma is a public-stage gene therapy company specializing in DdRNAi (DNA-directed RNA interference) technology, focused on rare and oncology indications. The company operates at modest scale with a pipeline of early-stage programs and limited commercial revenue.

Gene Therapy

Profile data last refreshed 23h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Benitec Biopharma

AI assessmentNot Hiring

No open roles listed right now. Follow Benitec Biopharma to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$75K

FY2024

Pipeline & Clinical Trials

BB-301: Dose escalation phase 1b cohort 1

Oculopharyngeal Muscular Dystrophy

Phase 1/2

Clinical Trials (1)

NCT06185673A Study to Evaluate the Safety and Clinical Activity of Intramuscular Doses of BB-301 Administered to Subjects With Oculopharyngeal Muscular Dystrophy With Dysphagia

Phase 1/2

Help build intelligence for Benitec Biopharma

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Access to proprietary DdRNAi platform technology with potential to address unmet needs in gene therapy
Public company status provides equity upside and longer-term stability compared to many early-stage biotech
Early-phase pipeline offers opportunity to shape clinical programs from Phase 1/2 stage forward

Watch Out For

Minimal revenue ($75K in FY2024) and consistent net losses ($19.6M–$21.8M) indicate pre-profitability trajectory
Zero active job openings and no disclosed hiring activity suggest limited growth headcount momentum
Only 2 clinical programs in early phases (Phase 1/2, Phase 2) with no Phase 3 programs or near-term regulatory catalysts

Generated by Claude from Benitec Biopharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

BB-401

Head and Neck Squamous Cell Carcinoma

Phase 2

Clinical Trials (1)

NCT03433027A Study of BB-401 in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 2 clinical trials

Top TAs: Oncology

SEC Filings: 2 available

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

1 pipeline

Marketed

Pipeline

Financials (FY2025)

R&D Spend

$16M22%

Net Income

-$22M

Cash

$51M

Source: SEC 10-K Filing